Across TCGA pan-cancer cohorts, FCF1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FCF1 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher FCF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FCF1 expression acts as an unfavorable survival marker.
SARC, BRCA, and SKCM are the cancer types where FCF1 Mutation most reproducibly stratifies survival.